MethylGene exercises royalty right in cancer drug collaboration with Celgene

Mon. September 22, 2008; Posted: 09:33 AM

Sep 22, 2008 (Datamonitor via COMTEX) -- CELG | Quote | Chart | News | PowerRating -- MethylGene, a clinical stage, biopharmaceutical company, has exercised its right to convert to a royalty stream and milestone arrangement with Celgene for MGCD0103 as provided under the license and collaboration agreement between the companies formed in January 2006.

By taking this action, MethylGene, after a 90-day transition period, will no longer be responsible for funding development costs required to obtain market approval for MGCD0103, and Celgene will assume 100% of the program costs for its licensed territories.

In addition, MethylGene will receive royalties in lieu of profit sharing in North America and is eligible to receive milestone payments of up to $141 million, as agreed in the original contract between the companies. Celgene will also pay royalties to MethylGene on annual net sales in its territories.

MethylGene's royalties in North America will increase from a floor of 13% to a higher royalty range based on annual net sales reflecting MethylGene's co-development funding and contribution for MGCD0103 to date.

The royalty rate in other Celgene territories outside of North America remains in a 10 to 13% range based on annual net sales. MethylGene maintains its rights under the original terms of the agreement to co-develop and co-promote subsequent compounds, including second generation histone deacetylase inhibitors and sirtuin inhibitors for cancer.

Donald Corcoran, president and CEO of MethylGene, said: "We believe that MGCD0103 presents a promising opportunity for the treatment of cancer. After thoughtful and careful analysis conducted with outside consultants, we have concluded that converting to a royalty at this time is financially advantageous.

"Moving forward, while participating in the upside and potential of MGCD0103, we will be focusing on developing the two compounds of which we own 100% - MGCD290 which is expected to enter into Phase I clinical trials by the end of this year and, in particular, MGCD265 which is in two Phase I clinical trials."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

For full details on Celgene Corp (CELG) click here. Celgene Corp (CELG) has Short Term PowerRatings of 5. Details on Celgene Corp (CELG) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.